



London, 15 November 2007
EMA/CHMP/536624/2007

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE
POST-AUTHORISATION SUMMARY OF POSITIVE OPINION*
for
XELEVIA

International Nonproprietary Name (INN): *sitagliptin*

On 15 November 2007 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion** to recommend the variation to the terms of the marketing authorisation for the medicinal product Xelevia. The Marketing Authorisation Holder for this medicinal product is Merck Sharp & Dohme Ltd.

The CHMP adopted new indications as follows:

- “to improve glycaemic control in combination with a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.
- to improve glycaemic control in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.”

Detailed conditions for the use of this product will be described in the updated Summary of Product Characteristics (SPC) which will be published in the revised European Public Assessment Report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

For information, the full indication for Xelevia will be as follows***:

“For patients with type 2 diabetes mellitus, Xelevia is indicated:

- to improve glycaemic control in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.
- **to improve glycaemic control in combination with a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.**
- **to improve glycaemic control in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.**

For patients with type 2 diabetes mellitus in whom use of a PPAR γ agonist (i.e. a thiazolidinedione) is appropriate, Xelevia is indicated:

- in combination with the PPAR γ agonist when diet and exercise plus the PPAR γ agonist alone do not provide adequate glycaemic control.”

* Summaries of positive opinion are published without prejudice to the Commission Decision, which will normally be issued within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the Opinion.

** Marketing Authorisation Holders may request a re-examination of any CHMP opinion, provided they notify the EMA in writing of their intention to request a re-examination within 15 days of receipt of the opinion.

*** The text in bold represents the new or the amended indication.